The Latest Breaking News from Merck

The U.S. Food and Drug Administration (FDA) has accepted the Menarini Group and Radius Health’s (NASDAQ:RDUS), New Drug Application (NDA) for elacestrant for patients with ER+/HER2- advanced or metastatic breast cancer. The agency has granted Priority Review designation and assigned a target action date of February 17, 2023. Radius Health…

Here's a roundup of top developments in the biotech space over the last 24 hours:

Merck & Co.’s Januvia, a popular diabetes drug, was found to be contaminated with a potential carcinogen.

The European Commission (EC) has approved AstraZeneca (NASDAQ: AZN) and Merck’s (NYSE: MRK) LYNPARZA as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline B

The U.S. Food and Drug Administration (FDA) has accepted for review MediWound’s (NASDAQ:MDWD) recently re-submitted Biologics License Application (BLA) for its lead asset NexoBrid for eschar removal (debridement) in adults with deep partial-thickness and/or full-thickness thermal burns. MediWound shares traded in a range of $1.6 to $1.76 on a day…

Here's a roundup of top developments in the biotech space over the last 24 hours:

The stock market rally made big moves amid a barrage of earnings and economic reports and another big Fed rate hike.

Merck stock tumbled amid a broad pharma turndown Thursday despite racking up more than $5 billion in sales for cancer drug, Keytruda.

Stocks rallied strongly Wednesday after Fed chief Jerome Powell hinted at slower Fed rate hikes. Watch out for day 2 reactions

Here's a roundup of top developments in the biotech space over the last 24 hours:

European Commission (EC) has approved AbbVie’s (NYSE:ABBV) lead asset RINVOQ (upadacitinib 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) for the treatment of adult patients with moderately to severely active ulcerative colitis. AbbVie shares traded in a range of $150.33 to $153.56 on a day volume…